← Oncology Approval Tracker

FDA DECISION ·

Tecentriq

atezolizumab · Genentech

FDA approvalNew or expanded indicationAlveolar soft part sarcoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults and pediatric patients age two or older with unresectable or metastatic alveolar soft part sarcoma.

LAMPGEN ANALYSIS

Why it matters

The approval extends PD-L1 blockade to a rare sarcoma across adult and pediatric age groups.

What research teams should watch

Verify specialist histology review, disease extent, and pediatric dosing criteria at referral.

PRIMARY RECORDS

Sources